Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology
Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.The cryptophycin ADC has shown
The Orphan Drug Designation strengthens LP-284's clinical development path and can provide for additional market exclusivity and commercial protection.Lantern has initiated a first-in-human Phase 1 trial (NCT06132503)